59,248 BridgeBio Pharma, Inc. $BBIO Shares Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 322.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,644 shares of the company’s stock after purchasing an additional 59,248 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in BridgeBio Pharma were worth $5,109,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BBIO. Silvant Capital Management LLC acquired a new position in shares of BridgeBio Pharma during the second quarter worth $28,000. Allworth Financial LP purchased a new position in BridgeBio Pharma in the second quarter valued at $31,000. Root Financial Partners LLC purchased a new position in BridgeBio Pharma in the third quarter valued at $28,000. SBI Securities Co. Ltd. raised its stake in BridgeBio Pharma by 55.3% in the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock valued at $29,000 after buying an additional 157 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BridgeBio Pharma in the second quarter valued at $44,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BBIO shares. Morgan Stanley upped their price objective on BridgeBio Pharma from $88.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday, November 13th. Jefferies Financial Group reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Truist Financial boosted their target price on BridgeBio Pharma from $102.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings cut BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. Nineteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, BridgeBio Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $104.42.

View Our Latest Research Report on BridgeBio Pharma

Insider Transactions at BridgeBio Pharma

In related news, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the sale, the chief accounting officer directly owned 120,687 shares of the company’s stock, valued at $8,792,047.95. This represents a 1.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer owned 495,686 shares in the company, valued at $34,241,988.88. This represents a 1.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.23% of the stock is currently owned by insiders.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO opened at $78.01 on Thursday. The company’s fifty day moving average price is $70.11 and its 200 day moving average price is $72.78. BridgeBio Pharma, Inc. has a 12 month low of $62.50 and a 12 month high of $93.42. The firm has a market capitalization of $15.20 billion, a P/E ratio of -25.66 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The company had revenue of $353.17 million during the quarter, compared to analysts’ expectations of $293.47 million. During the same period last year, the firm earned ($0.95) earnings per share. BridgeBio Pharma’s revenue was up 192.6% on a year-over-year basis. On average, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 EPS for the current year.

BridgeBio Pharma Company Profile

(Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

Read More

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.